Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Stem Cell Cartilage Regeneration Market – Insights

Increasing adoption of minimally invasive surgery procedures is expected to drive growth of stem cell cartilage regeneration market. Stem cell therapy for knees, minimally invasive procedure has the potential to decrease inflammation, halt progression of arthritic damage, repair joint cartilage, and delay or avoid knee replacement surgery. Injection of progenitor cells, especially mesenchymal stem cells (MSCs) is found to be an effective and better solution for repairing degenerative cartilage compared to implantation of differentiated cells such as articular cartilage.

Increasing epidemic of osteoarthritis among the global population is expected to increase adoption of efficient and promising treatment such as stem cell therapy during the forecast period. For instance, according to the data findings published by Arthritis Foundation in November 2017, arthritis was the leading cause of disability among adults in the U.S. Over 53 million adults worldwide suffered from arthritis, which refers to over 100 types of joint diseases. This is expected to increase 49% to reach over 78.4 million by 2040.

The global stem cell cartilage regeneration market is estimated to be valued at US$ 298.3 million in 2019, and is expected to exhibit a CAGR of 9.1% over the forecast period (2020-2027).

Global Stem Cell Cartilage Regeneration Market Share (%) Analysis, By Stem Cells, 2019

Stem Cell Cartilage Regeneration  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Stem Cell Cartilage Regeneration Market - Regional Insights

On the basis of region, the global stem cell cartilage regeneration market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the most lucrative region for growth of the stem cell cartilage regeneration market over the forecast period, due to high presence of key players in the region. Key players such as Vericel Corporation, Osiris Therapeutics, among others are focusing on various growth strategies such as gaining regulatory product approvals and launching innovative stem cell-based cartilage regeneration products and technologies in the market.

Furthermore, increasing geriatric population, who are more prone to degenerative disorders such as osteoarthritis among the U.S. population, is further expected to propel growth of the stem cell cartilage regeneration market in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), July 2018 data findings, from 2013-2015, around 54.4 million U.S. adults (22.7% of total U.S. population) annually suffered from some form of arthritis such as rheumatoid arthritis, gout, lupus, or fibromyalgia.

Asia Pacific stem cell cartilage regeneration market revenue is expected to witness significant growth over the forecast period. In India, stem cell-based cartilage regeneration procedures are conducted by various hospital and clinics. Moreover, hospitals such as Apollo, TOSH (Trauma & Orthopaedic Speciality Hospital), among others are conducting stem cell-based knee arthritis surgery procedures.

Global Stem Cell Cartilage Regeneration Market, Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Stem Cell Cartilage Regeneration  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Global Stem Cell Cartilage Regeneration Market - Competitive Landscape

Major players operating in the global stem cell cartilage regeneration market include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.

In cartilage regeneration, stem cells have the potential for multiple differentiation and self-replication, making it an ideal choice for use as seed cells. Growing regenerative medicine industry and increasing demand for stem cells in the development of various types of cell therapies are expected to drive growth of the market over the forecast period. Mesenchymal stem cells are the most widely applied stem cells in the field of cartilage regeneration.

Furthermore, adult stem cells have potential to differentiate into cartilage, bone, fat or soft tissue. Stem cell-based therapy has become a key focus in functional replacement of cartilage regeneration. Adult stem cells can be extracted by minimally invasive methods from fat tissue and bone marrow. Fat derived stem cells exhibits an enhanced ability to differentiate into cartilage and are found in higher numbers than bone marrow.

Market Dynamics

Government agencies are focusing on policies to enhance adoption of stem cell therapies, which is expected to drive growth of stem cell cartilage regeneration market over the forecast period. For instance, in December 2016, the 21st Century Cures Act (Cures Act) was signed into law by the U.S. FDA, thereby allowing legislation for an expedited approval path for cellular medicines designated as regenerative medicine advanced therapies (RMATs) for patients who need it.

Furthermore, growing engagement of various key players in developing stem cell therapy as a commercially viable, safer, more efficient, and less expensive therapeutic agent for cartilage regeneration is expected to drive growth of the global stem cell cartilage regeneration market. For instance, in January 2018, a group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which previously was incurable and had no effective therapies. Following the first in-human clinical trial at Osaka University Hospital, the surgery of the first patient was performed in the Phase III clinical study to confirm efficacy and safety of this therapy.

Moreover, growing osteoarthritis incidence among the global population is expected to drive adoption of stem cell cartilage regeneration therapy. For instance, according to the Arthritis Foundation, November 2017 data findings, with the increase in global geriatric population, degenerative disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050.

Key features of the study:

  • This report provides in-depth analysis of the market, global stem cell cartilage regeneration market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2019-2027, considering 2018 as the base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global stem cell cartilage regeneration market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies.
  • Key players covered as a part of this study include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, governmental initiatives, market expansions, and marketing tactics.
  • The global stem cell cartilage regeneration market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of reprocessed medical devices, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Stem Cell Cartilage Regeneration Market, By Stem Cell Type:
    • Hematopoietic Stem Cells (HSCs)
    • Pluripotent Stem Cells (iPSC/ESCs)
    • Mesenchymal Stem Cells (MSCs)
  • Global Stem Cell Cartilage Regeneration Market, By Treatment:
    • Microfracture
    • Osteochondral Transplant
    • Autologous Chondrocyte Implantation
    • Stem Cell Injections
  • Global Stem Cell Cartilage Regeneration Market, By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
  • Global Stem Cell Cartilage Regeneration Market, By Region :
    • North America
      • By Stem Cell Type
        • Hematopoietic Stem Cells (HSCs)
        • Pluripotent Stem Cells (iPSC/ESCs)
        • Mesenchymal Stem Cells (MSCs
        • Gastroenterology
      • By Treatment
        • Microfracture
        • Osteochondral Transplant
        • Autologous Chondrocyte Implantation
        • Stem Cell Injections
      • By End User
        • Hospitals & Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • S.
        • Canada
    • Latin America
      • By Stem Cell Type
        • Hematopoietic Stem Cells (HSCs)
        • Pluripotent Stem Cells (iPSC/ESCs)
        • Mesenchymal Stem Cells (MSCs
        • Gastroenterology
      • By Treatment
        • Microfracture
        • Osteochondral Transplant
        • Autologous Chondrocyte Implantation
        • Stem Cell Injections
      • By End User
        • Hospitals & Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Stem Cell Type
        • Hematopoietic Stem Cells (HSCs)
        • Pluripotent Stem Cells (iPSC/ESCs)
        • Mesenchymal Stem Cells (MSCs
        • Gastroenterology
      • By Treatment
        • Microfracture
        • Osteochondral Transplant
        • Autologous Chondrocyte Implantation
        • Stem Cell Injections
      • By End User
        • Hospitals & Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Stem Cell Type
        • Hematopoietic Stem Cells (HSCs)
        • Pluripotent Stem Cells (iPSC/ESCs)
        • Mesenchymal Stem Cells (MSCs
        • Gastroenterology
      • By Treatment
        • Microfracture
        • Osteochondral Transplant
        • Autologous Chondrocyte Implantation
        • Stem Cell Injections
      • By End User
        • Hospitals & Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Stem Cell Type
        • Hematopoietic Stem Cells (HSCs)
        • Pluripotent Stem Cells (iPSC/ESCs)
        • Mesenchymal Stem Cells (MSCs
        • Gastroenterology
      • By Treatment
        • Microfracture
        • Osteochondral Transplant
        • Autologous Chondrocyte Implantation
        • Stem Cell Injections
      • By End User
        • Hospitals & Clinics
        • Ambulatory Surgical Centers
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Stem Cell Type
        • Hematopoietic Stem Cells (HSCs)
        • Pluripotent Stem Cells (iPSC/ESCs)
        • Mesenchymal Stem Cells (MSCs
        • Gastroenterology
      • By Treatment
        • Microfracture
        • Osteochondral Transplant
        • Autologous Chondrocyte Implantation
        • Stem Cell Injections
      • By End User
        • Hospitals & Clinics
        • Ambulatory Surgical Centers
        • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Theracell Advanced Biotechnology Ltd *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Orthocell Ltd.
    • Xintela AB
    • CellGenix GmbH
    • Merck KGaA
    • Osiris Therapeutics, Inc.
    • BioTissue SA
    • Vericel Corporation

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Stem Cell Type
      • Market Snippet, By Treatment
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Key Developments
    • PESTLE Analysis
  4. Global Stem Cell Cartilage Regeneration Market, By Stem Cell Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hematopoietic Stem Cells (HSCs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Pluripotent Stem Cells (iPSC/ESCs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Mesenchymal Stem Cells (MSCs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  5. Global Stem Cell Cartilage Regeneration Market, By Treatment, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Microfracture
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Osteochondral Transplant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Autologous Chondrocyte Implantation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Stem Cell Injections
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  6. Global Stem Cell Cartilage Regeneration Market, By End User, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals & Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
    • Ambulatory Surgical Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
  7. Global Stem Cell Cartilage Regeneration Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • North America
      • Market Size and Forecast, By Stem Cell Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Treatment, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Stem Cell Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Treatment, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Stem Cell Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Treatment, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Stem Cell Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Treatment, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Stem Cell Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Treatment, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2019 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Stem Cell Type, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Treatment, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2019 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Theracell Advanced Biotechnology Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Orthocell Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Xintela AB
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • CellGenix GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Osiris Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • BioTissue SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Vericel Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 32 market data tables and 24 figures on “Stem Cell Cartilage Regeneration Market” – Global forecast to 2027”

Frequently Asked Questions

The global stem cell cartilage regeneration market is estimated to surpass US$ 596.5 Million by 2027.
Major players operating in the global stem cell cartilage regeneration market include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.
Among stem cell type, mesenchymal stem cellssegment is expected to hold dominant position in the global stem cell cartilage regeneration market.
Increasing epidemic of osteoarthritis among the global population is one of the major factors that is expected to propel growth of the market over the forecast period.
The global stem cell cartilage regeneration market is estimated to exhibit a CAGR of 9.1% over the forecast period (2019-2027).
Among regions, North America is expected to hold dominant position in the global stem cell cartilage regeneration market over the forecast period.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner